4.5 Article

Resistance to antidepressant treatment is associated with polymorphisms in the leptin gene, decreased leptin mRNA expression, and decreased leptin serum levels

期刊

EUROPEAN NEUROPSYCHOPHARMACOLOGY
卷 23, 期 7, 页码 653-662

出版社

ELSEVIER
DOI: 10.1016/j.euroneuro.2012.08.010

关键词

Depression; Leptin; Treatment response; Gene expression; Pharmacogenetics

资金

  1. Max Planck Society
  2. German Federal Ministry for Education and Research (BMBF) in the framework of the National Genome Research Network (NGFN2 and NGFN-Plus) [FKZ 01GSO481]
  3. BMBF Program [01ES0811]
  4. NIMH [N01 MH-90003, R01 MH-072802]
  5. European Commission [LSHB-CT-2003-503428]
  6. Biomedical Research Centre for Mental Health at the Institute of Psychiatry, King's College London and South London
  7. Maudsley National Health Service Foundation Trust (National Institute for Health Research, United Kingdom)
  8. Medical Research Council, United Kingdom [G0701420]
  9. MRC [G0701420] Funding Source: UKRI
  10. Medical Research Council [G0701420, G9817803B] Funding Source: researchfish

向作者/读者索取更多资源

Leptin, a peptide hormone from adipose tissue and key player in weight regulation, has been suggested to be involved in sleep and cognition and to exert antidepressant-like effects, presumably via its action on the HPA-axis and hippocampal function. This led us to investigate whether genetic variants in the leptin gene, the level of leptin mRNA-expression and leptin serum concentrations are associated with response to antidepressant treatment. Our sample consisted of inpatients from the Munich Antidepressant Response Signature (MARS) project with weekly Hamilton Depression ratings, divided into two subsamples. In the exploratory sample (n=251) 17 single nucleotide polymorphisms (SNPs) covering the leptin gene region were genotyped. We found significant associations of several SNPs with impaired antidepressant treatment outcome and impaired cognitive performance after correction for multiple testing. The SNP (rs10487506) showing the highest association with treatment response (p=3.9 x 10(-5)) was analyzed in the replication sample (n=358) and the association could be verified (p=0.021) with response to tricyclic antidepressants. In an additional meta-analysis combining results from the MARS study with data from the Genome-based Therapeutic Drugs for Depression (GENDEP) and the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) studies, nominal associations of several polymorphisms in the upstream vicinity of rs10487506 with treatment outcome were detected (p=0.001). In addition, we determined leptin mRNA expression in lymphocytes and leptin serum levels in subsamples of the MARS study. Unfavorable treatment outcome was accompanied with decreased leptin mRNA and leptin serum levels. Our results suggest an involvement of leptin in antidepressant action and cognitive function in depression with genetic polymorphisms in the leptin gene, decreased leptin gene expression and leptin deficiency in serum being risk factors for resistance to antidepressant therapy in depressed patients. (C) 2012 Elsevier B.V. and ECNP. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据